Unofficial Copy C3 1997 Regular Session 7lr1213

By: Senator Bromwell Senators Bromwell, Hafer, Roesser, and Teitelbaum

Introduced and read first time: January 13, 1997

Assigned to: Finance

Committee Report: Favorable with amendments

Senate action: Adopted

Read second time: March 11, 1997

CHAPTER ____

1 AN ACT concerning

2 Experimental Medical Care Disclosure Act

3	FOR the purpose of requiring certain insurers, nonprofit health service plans, and health
4	maintenance organizations carriers to establish or subscribe to or contract for and
5	follow a certain process when evaluating emerging medical and surgical treatments
6	for the purpose of making certain coverage decisions a certain purpose; requiring
7	certain insurers, nonprofit heath service plans, and health maintenance
8	organizations carriers to make certain disclosures to certain providers, enrollees,
9	and prospective enrollees under certain circumstances; specifying the provisions of
10	the process; requiring certain carriers to provide a description of the process to
11	certain persons under certain circumstances; requiring certain insurers, nonprofit
12	health service plans, and health maintenance organizations carriers to file a certain
13	report make a certain filing with the Insurance Commissioner; specifying the
14	contents of the report; requiring the Commissioner to make the filing available or
15	provide a copy of the filing to certain persons under certain circumstances;
16	authorizing the Commissioner to grant certain waivers under certain circumstances;
17	authorizing the Commissioner to issue certain orders; authorizing the
18	Commissioner to adopt regulations; providing for the application of this Act;
19	providing a certain immunity from liability for certain individuals; defining certain
20	terms; and generally relating to requiring certain insurers, nonprofit health service
21	plans, and health maintenance organizations carriers to establish and follow a
22	certain process when evaluating emerging medical and surgical treatments for the
23	purpose of making cartain coverage decisions a certain purpose

- 24 BY adding to
- 25 Article Insurance
- 26 Section 15-121
- 27 Annotated Code of Maryland

2	
1	(1995 Volume and 1996 Supplement)
2	(As enacted by Chapter (H.B. 11) of the Acts of the General Assembly of 1997)
3	BY adding to
4	Article Courts and Judicial Proceedings
5	Section 5-399.8
6	Annotated Code of Maryland
7	(1995 Replacement Volume and 1996 Supplement)
8	BY adding to
9	Article - Health - General
10	Section 19-706(n)
11	Annotated Code of Maryland
12	(1996 Replacement Volume and 1996 Supplement)
	(· · · · · · · · · · · · · · · · · · ·
13	SECTION 1. BE IT ENACTED BY THE GENERAL ASSEMBLY OF
14	MARYLAND, That the Laws of Maryland read as follows:
15	Article - Insurance
16	15-121.
17	(A) (1) IN THIS SECTION THE FOLLOWING WORDS HAVE THE MEANINGS
18	INDICATED.
10	
19	(2) "CARRIER" MEANS:
	(-)
20	(I) AN INSURER;
	()
21	(II) A NONPROFIT HEALTH SERVICE PLAN;
	(,,,,,,,,
22	(III) A HEALTH MAINTENANCE ORGANIZATION;
	(/
23	(IV) A DENTAL PLAN ORGANIZATION; OR
	(17) II BENTIEL EL TOROLENE INON, OR
24	(V) ANY PERSON OR ENTITY ACTING AS A THIRD PARTY
	ADMINISTRATOR; OR
23	ADMINISTRATOR, OK
26	(VI) EXCEPT FOR A MANAGED CARE ORGANIZATION AS DEFINED
	* * *
	IN TITLE 15, SUBTITLE 1 OF THE HEALTH - GENERAL ARTICLE, AN ENTITY THAT HAS
	ORGANIZED A PROVIDER NETWORK FOR THE PURPOSE OF CONTRACTING
29	<u>DIRECTLY WITH A PURCHASER TO PROVIDE HEALTH CARE SERVICES TO</u>
30	INDIVIDUALS OR GROUPS UNDER A CAPITATED OR OTHER RISK-SHARING
31	<u>ARRANGEMENT</u> .
32	(3) "CONTRACT" MEANS ANY WRITTEN AGREEMENT BETWEEN A
33	PROVIDER AND A CARRIER FOR THE PROVIDER TO RENDER HEALTH CARE
34	SERVICES TO ENROLLEES OF THE CARRIER.
35	(4) "DIAGNOSTIC SERVICES" MEANS ANY MEDICAL OR SURGICAL
36	SERVICE OR PROCEDURE THAT ALLOWS A PROVIDER TO IDENTIFY OR DIAGNOSE A
37	HUMAN DISEASE OR DISORDER.

1 2	(5) "ENROLLEE" MEANS ANY PERSON <u>OR SUBSCRIBER</u> ENTITLED TO HEALTH CARE BENEFITS FROM A CARRIER.
3	(6) "HEALTH CARE SERVICES" MEANS A HEALTH OR MEDICAL CARE PROCEDURE OR SERVICE RENDERED BY A PROVIDER THAT:
5 6	(I) PROVIDES TESTING, DIAGNOSIS, OR TREATMENT OF A HUMAN DISEASE OR DYSFUNCTION; OR
-	(II) DISPENSES DRUGS, MEDICAL DEVICES, MEDICAL APPLIANCES OR MEDICAL GOODS FOR THE TREATMENT OF A HUMAN DISEASE OR DYSFUNCTION.
12	(7) (I) "PROVIDER" MEANS A PERSON OR ENTITY LICENSED, CERTIFIED, OR OTHERWISE AUTHORIZED UNDER THE HEALTH OCCUPATIONS ARTICLE OR THE HEALTH - GENERAL ARTICLE TO PROVIDE HEALTH CARE SERVICES.
14	(II) "PROVIDER" INCLUDES:
15	1. A HEALTH CARE FACILITY;
16	2. A PHARMACY;
17	3. A PROFESSIONAL SERVICES CORPORATION;
18	4. A PARTNERSHIP;
19	5. A LIMITED LIABILITY COMPANY;
20	6. A PROFESSIONAL OFFICE; OR
	7. ANY OTHER ENTITY LICENSED OR AUTHORIZED BY LAW TO PROVIDE OR DELIVER PROFESSIONAL HEALTH CARE SERVICES THROUGH OR ON BEHALF OF A PROVIDER.
	(8) "THERAPEUTIC SERVICES" MEANS ANY MEDICAL OR SURGICAL SERVICE OR PROCEDURE THAT A PROVIDER CAN USE TO TREAT A HUMAN DISEASE OR DISORDER.
	(B) THIS SECTION APPLIES TO ANY CARRIER THAT PROVIDES HEALTH CARE SERVICES TO ENROLLEES OR OTHERWISE MAKES HEALTH CARE SERVICES AVAILABLE TO ENROLLEES THROUGH CONTRACTS WITH PROVIDERS.
30	(C) THE SECTION DOES NOT:
33	(1) APPLY TO ANY COSMETIC OR MEDICALLY UNNECESSARY SERVICE OR PROCEDURE THAT TYPICALLY WOULD BE EXCLUDED FROM COVERAGE BY ANY CARRIER THAT ISSUES OR DELIVERS CONTRACTS OR POLICIES OF HEALTH INSURANCE IN THE STATE; $\frac{AND}{OR}$
35 36	(2) AFFECT THE RIGHT OF AN ENROLLEE TO APPEAL ANY ADVERSE DECISION BY A CARRIER THROUGH THE CARRIER'S APPEAL PROCESS.

1 (D) (1) EACH CARRIER SHALL DISCLOSE TO PROVIDERS, ENROLLEES, AND
2 PROSPECTIVE ENROLLEES PROVIDERS AND ENROLLEES THE CARRIER'S
3 DEFINITION OF "EXPERIMENTAL MEDICAL CARE".
4 (2) THE CARRIER SHALL DISCLOSE THE DEFINITION IN:
4 (2) THE CARRIER SHALL DISCLOSE THE DEFINITION IN:
5 (I) CONTRACTS OFFERED TO PROVIDERS THAT MAY RENDER
6 DIRECT HEALTH CARE SERVICES TO THE ENROLLEES OF THE CARRIER; AND
7 (II) MARKETING MATERIALS AND ENROLLMENT MATERIALS OF
·
8 THE CARRIER THAT ARE PROVIDED TO CURRENT ENROLLEES AND PROSPECTIVE
9 ENROLLEES <u>, AS APPROPRIATE</u> .
10 (3) THE DEFINITION:
(I) CHALL INCLUDE THE CENEDAL CRITERIA AND PROCESS THAT
11 (I) SHALL INCLUDE THE GENERAL CRITERIA AND PROCESS THAT
12 THE CARRIER FOLLOWS FOR INDIVIDUAL ENROLLEES OR FOR THE ENTIRE
13 ENROLLED POPULATION IN EVALUATING WHETHER AN EMERGING MEDICAL OR
14 SURGICAL TREATMENT WILL BE COVERED BY THE CARRIER: AND
15 (II) SHALL DE DINIDING ON THE CARDIED ENDOLLEES AND
15 (II) SHALL BE BINDING ON THE CARRIER, ENROLLEES, AND
16 PROVIDERS FOR THE PURPOSE OF RESOLVING DISPUTES THAT ARISE OVER
17 WHETHER A MEDICAL OR SURGICAL TREATMENT IS OR IS NOT EXPERIMENTAL,
18 AND THEREFORE, COVERED BY THE CARRIER.
19 (E) (1) EACH CARRIER SHALL ESTABLISH A SYSTEMATIC, SCIENTIFIC
20 PROCESS TO FOLLOW FOR EVALUATING EMERGING MEDICAL AND SURGICAL
21 TREATMENTS TO ENSURE THAT PROVIDERS AND ENROLLEES HAVE ACCESS TO THE
22 LATEST APPROPRIATE TREATMENTS.
23 (2) THE PROCESS SHALL INCLUDE:
25 (2) THE TROUBLE BY CELEBE.
24 (I) ONGOING ANALYSES BY THE MEDICAL DIRECTOR OF THE
25 CARRIER AND THE MEDICAL POLICY STAFF OF THE CARRIER OF PUBLISHED,
26 PEER REVIEWED MEDICAL LITERATURE, AND THE FINDINGS AND PUBLICATIONS
27 OF STATE AND FEDERAL AGENCIES; AND
28 (II) ONGOING DIALOGUE WITH OTHER CLINICAL EXPERTS IN THE
29 MEDICAL COMMUNITY FOR THE PURPOSE OF EVALUATING WHETHER EMERGING
30 MEDICAL OR SURGICAL TREATMENTS HAVE BECOME AN APPROPRIATE STANDARD
31 OF CARE FOR SPECIFIED HUMAN DISEASES OR DISORDERS.
32 (3) THE CARRIER SHALL IDENTIFY LEADING CLINICAL EXPERTS IN
33 RECOGNIZED MEDICAL AND SURGICAL SPECIALITIES AND SURSPECIALTIES FOR
34 THE PURPOSE OF HAVING THE CLINICAL EXPERTS PROVIDE THE CARRIER WITH
35 DIALOGUE ON AND ANALYSES OF THE STATUS OF EMERGING MEDICAL AND
36 SURGICAL TREATMENTS.
37 (4) THE CLINICAL EXPERTS IDENTIFIED BY THE CARRIER:
20 (I) CHALL DE ACTIVELV INVOLVED IN THE DROVICION OF DIRECT
38 (I) SHALL BE ACTIVELY INVOLVED IN THE PROVISION OF DIRECT
39 HEALTH CARE SERVICES TO PATIENTS WITH THE HUMAN DISEASES OR DISORDERS

	BEING EVALUATED, WHETHER OR NOT THE PATIENTS ROUTINELY TREATED BY THE PROVIDER ARE ENROLLEES OF THE CARRIER;
3	(II) MAY NOT BE AN EMPLOYEE OF THE CARRIER;
4	(III) SHALL BE BOARD CERTIFIED IN THE PERTINENT OR
	APPROPRIATE SPECIALTY OR SUBSPECIALTY AREA; AND
6	(IV) SHALL BE GENERALLY RECOGNIZED BY THEIR PEERS TO BE
	AUTHORITATIVE RESOURCES IN THE CLINICAL AREA BEING EVALUATED, AS EVIDENCED BY:
9	1. FACULTY APPOINTMENTS;
10	2. AUTHORSHIP OF A SIGNIFICANT BODY OF
11	PEER REVIEWED CLINICAL LITERATURE IN THE RELEVANT SPECIALITY AREA; AND
12	3. A DEMONSTRATED HISTORY OF LEADERSHIP IN LOCAL,
13	STATE, AND NATIONAL PROFESSIONAL ASSOCIATIONS AND NONPROFIT PATIENT
	AND COMMUNITY ADVOCACY ORGANIZATIONS THAT ADDRESS THE DISEASES AND
15	SPECIALTY AREAS IN QUESTION.
16	(5) EACH CARRIER SHALL FILE ANNUALLY WITH THE COMMISSIONER
17	THE CREDENTIALING CRITERIA THE CARRIER HAS UTILIZED IN SELECTING THE
	CLINICAL EXPERTS AND OTHER SOURCES UTILIZED BY THE CARRIER IN
	EVALUATING A DIAGNOSTIC OR THERAPEUTIC SERVICE THAT IS PART OF AN
20	EMERGING MEDICAL OR SURGICAL TREATMENT.
21	(F) A CARRIER'S DECISION TO PROVIDE COVERAGE FOR AN EMERGING
22	MEDICAL OR SURGICAL TREATMENT SHALL RESULT FROM THE CONSENSUS OF
	OPINION FROM ITS OWN ANALYSIS AND THE KNOWLEDGE PROVIDED TO THE
	CARRIER FROM THE CLINICAL EXPERTS IDENTIFIED BY THE CARRIER UNDER
25	SUBSECTION (E)(3) OF THIS SECTION.
26	(G) (1) EACH CARRIER, IN CONSULTATION WITH THE CLINICAL EXPERTS
27	IDENTIFIED BY THE CARRIER UNDER SUBSECTION (E)(3) OF THIS SECTION, SHALL
	DECIDE THE APPROPRIATE PATIENT SELECTION CRITERIA FOR AN EMERGING
	MEDICAL OR SURGICAL TREATMENT FOR THE CARRIER'S AND THE CLINICAL
	EXPERT'S REVIEW AND FOR WHICH COVERAGE BY THE CARRIER IS TO BE
31	EXTENDED.
32	(2) A CARRIER MAY USE THE PATIENT SELECTION CRITERIA AND
	OTHER GUIDELINES AGREED ON WITH THE CLINICAL EXPERTS TO APPROVE OR
٠.	DENY COVERAGE FOR EMERGING MEDICAL AND SURGICAL TREATMENTS FOR ITS
35	ENROLLEES.
36	(H) (1) A CARRIER'S MEDICAL DIRECTOR AND MEDICAL POLICY STAFF
	MAY NOT MAKE COVERAGE DECISIONS ON LIFESAVING EMERGING MEDICAL OR
	SURGICAL TREATMENTS WITHOUT FIRST CONSULTING THE CLINICAL EXPERTS
39	IDENTIFIED BY THE CARRIER UNDER SUBSECTION (E)(3) OF THIS SECTION.
40	(2) A CARRIER SHALL HAVE THE RIGHT TO REEVALUATE AREAS OF
41	DISPUTE BETWEEN THE CARRIER AND THE CLINICAL EXPERTS ANNUALLY TO

1	DETERMINE WHETHER SCIENTIFIC ADVANCES WARRANT A CHANGE IN THE
2	CARRIER'S COVERAGE AND PAYMENT POLICY FOR EMERGING MEDICAL AND
3	SURGICAL TREATMENTS.
J	SURGICIAL TREATMENTS.
4	(I) (1) EACH CARRIER SHALL FILE ANNUALLY WITH THE COMMISSIONER A
	DETAILED REPORT ON ALL THE CLINICAL AREAS AND DIAGNOSTIC AND
_	
-	THERAPEUTIC SERVICES EVALUATED THAT WERE PART OF EMERGING MEDICAL
	AND SURGICAL TREATMENTS, IN CONSULTATION WITH THE CLINICAL EXPERTS
8	IDENTIFIED BY THE CARRIER UNDER SUBSECTION (E)(3) OF THIS SECTION, DURING
9	THE PAST YEAR.
10	(2) THE REPORT SHALL INCLUDE:
11	(I) A SUMMARY DESCRIPTION OF EACH CLINICAL ISSUE OR
12	DIAGNOSTIC OR THERAPEUTIC SERVICE THAT WAS EVALUATED;
12	DINGWOOTIE OK THEKNI EOTIE SEKVICE THAT WAS EVALOTIED;
13	(II) EOD EACH DIACNOSTIC OD THED A DELITIC SEDVICE. A
	(II) FOR EACH DIAGNOSTIC OR THERAPEUTIC SERVICE, A
	SUMMARY OF THE FINDINGS OF THE CARRIER AND THE CLINICAL EXPERTS FROM
15	THE REVIEW OF PUBLISHED, PEER-REVIEWED MEDICAL LITERATURE; AND
16	(III) FOR EACH DIAGNOSTIC OR THERAPEUTIC SERVICE, A
17	SUMMARY OF THE OPINIONS OF THE CLINICAL EXPERTS ON WHETHER THE
18	DIAGNOSTIC OR THERAPEUTIC SERVICE IS CONSIDERED A STANDARD OF CARE FOR
19	THE LOCAL COMMUNITY.
20	(E) EACH CARRIER SHALL ESTABLISH OR SUBSCRIBE OR CONTRACT TO
	· · · · · · · · · · · · · · · · · · ·
	PROVIDE A SYSTEMATIC, SCIENTIFIC PROCESS TO FOLLOW FOR EVALUATING
22	EMERGING MEDICAL AND SURGICAL TREATMENTS TO ENSURE THAT SUBSCRIBERS
23	HAVE ACCESS TO THE LATEST APPROPRIATE TREATMENTS.
24	(F) THE PROCESS ESTABLISHED OR SUBSCRIBED TO OR CONTRACTED FOR
25	BY A CARRIER UNDER SUBSECTION (E) OF THIS SECTION SHALL INCLUDE:
	-
26	(1) A COMPREHENSIVE REVIEW OF MEDICAL LITERATURE AND DATA
	EVALUATION; AND
۷,	EVALUATION, AND
30	(A) DIDLE FROM DUNGLOUNG AND OFFIED REGOGNIZED EXPERTS
28	(2) INPUT FROM PHYSICIANS AND OTHER RECOGNIZED EXPERTS:
29	(I) WHO ARE NOT EMPLOYEES OF THE CARRIER; AND
30	(II) WHO:
31	1. ARE CURRENTLY TREATING PATIENTS FOR THE DISEASE
	OR CONDITION BEING EVALUATED;
2	OR CONDITION BEING EVALUATED,
22	A ARE DO ARD GERTIFIED IN THE REPTRIENT OFFICIAL TV
33	2. ARE BOARD CERTIFIED IN THE PERTINENT SPECIALTY
34	OR SUBSPECIALTY AREA OF THE DISEASE OR CONDITION BEING EVALUATED;
35	3. ARE GENERALLY RECOGNIZED BY THEIR PEERS TO BE
36	AUTHORITATIVE RESOURCES IN THE CLINICAL AREA BEING EVALUATED AS
	EVIDENCED BY:
•	_

1	B. AUTHORSHIP OF A SIGNIFICANT BODY OF
2	PEER-REVIEWED CLINICAL LITERATURE IN THE PERTINENT SPECIALTY OR
	SUBSPECIALTY AREA; OR
	DODGE DONIEL TIMES IN COL
4	C. A DEMONSTRATED HISTORY OF LEADERSHIP IN LOCAL,
	STATE, OR NATIONAL PROFESSIONAL ASSOCIATIONS AND NONPROFIT PATIENT AND
	COMMUNITY ADVOCACY ORGANIZATIONS THAT ADDRESS THE DISEASE OR
7	CONDITION AND THE SPECIALTY OR SUBSPECIALTY AREA IN QUESTION; OR
8	4. HAVE A DEMONSTRATED HISTORY OF SUBSTANTIAL
9	EXPERIENCE AND PRACTICAL KNOWLEDGE IN THE SPECIALTY OR SUBSPECIALTY
10	AREA IN QUESTION.
11	(G) A CARRIER'S DECISION TO PROVIDE COVERAGE FOR AN EMERGING
12	MEDICAL OR SURGICAL TREATMENT SHALL RESULT FROM THE CONSENSUS OF
	OPINION FROM ITS OWN ANALYSIS AND THE KNOWLEDGE PROVIDED TO THE
	CARRIER FROM THE PROCESS IDENTIFIED BY THE CARRIER IN SUBSECTION (F) OF
13	THIS SECTION.
	AN ELGIN GARRED DA GOLVANIA GERMANIA EN ELGIN DA GARRED GA
16	(H) EACH CARRIER, IN CONJUNCTION WITH THE CLINICAL EXPERTS
17	IDENTIFIED BY THE CARRIER UNDER SUBSECTION (F)(2) OF THIS SECTION, SHALL
18	DECIDE THE PATIENT SELECTION CRITERIA FOR AN EMERGING MEDICAL OR
19	SURGICAL TREATMENT FOR WHICH COVERAGE BY THE CARRIER IS TO BE
20	PROVIDED.
21	(I) EACH CARRIER SHALL PROVIDE A DESCRIPTION OF THE PROCESS
	IDENTIFIED BY THE CARRIER UNDER SUBSECTION (F) OF THIS SECTION TO
	ENROLLEES AND CONTRACTING PROVIDERS AND ALL OTHER PROVIDERS ON
24	REQUEST.
25	(J) (1) A CARRIER'S COVERAGE DECISION ON AN EMERGING MEDICAL OR
26	SURGICAL TREATMENT SHALL BE IN COMPLIANCE WITH § 19-1305.2 OF THE HEALTH
27	- GENERAL ARTICLE, WHEN BEING APPEALED BY AN ENROLLEE.
28	(2) A CARRIER MAY REEVALUATE ANNUALLY WHETHER SCIENTIFIC
29	ADVANCES WARRANT A CHANGE IN THE CARRIER'S COVERAGE AND PAYMENT
	POLICY FOR AN EMERGING MEDICAL OR SURGICAL TREATMENT.
50	TOLIC I TOK AN EMEROING MEDICAL OR SURGICAL TREATMENT.
21	(IZ) (1) EACH CARRIED CHALLER E ANNHALLY WITH THE COMMISSIONER A
31	(K) (1) EACH CARRIER SHALL FILE ANNUALLY WITH THE COMMISSIONER A
	SUMMARY DESCRIPTION OF THE CLINICAL ISSUES AND DIAGNOSTIC AND
33	THERAPEUTIC SERVICES THAT WERE EVALUATED AND THE CONCLUSION OF THE
34	EVALUATION, INCLUDING THE OPINIONS OF THE CLINICAL EXPERTS.
35	(3) (2) THE COMMISSIONER SHALL:
36	(I) MAKE EACH CARRIER'S REPORT FILING UNDER PARAGRAPH
	(1) OF THIS SUBSECTION AVAILABLE TO THE PUBLIC FOR INSPECTION AND REVIEW;
	AND
30	AND
20	(II) DROVIDE A CODY OF A CARRIEDIS DEDORGER BY CARRED
39	(II) PROVIDE A COPY OF A CARRIER'S REPORT FILING UNDER
	PARAGRAPH (1) OF THIS SUBSECTION TO ANY PERSON UPON REQUEST IN A TIMELY
41	MANNER AND AT A REASONABLE COST TO THE PERSON.

	(J) AN INDIVIDUAL SERVING AS A CLINICAL EXPERT FOR THE PURPOSES OF THIS SECTION SHALL HAVE THE IMMUNITY FROM LIABILITY DESCRIBED UNDER § 5-399.8 OF THE COURTS AND JUDICIAL PROCEEDINGS ARTICLE.
6	(K) EACH CARRIER SHALL INCLUDE IN SUMMARY FORM INFORMATION ON THE PROCESS THAT THE CARRIER IS REQUIRED UNDER THIS SECTION TO ESTABLISH AND FOLLOW IN EVALUATING EMERGING MEDICAL AND SURGICAL TREATMENTS FOR THE PURPOSE OF MAKING COVERAGE DECISIONS IN:
	(1) THE MARKETING AND ENROLLMENT MATERIALS OF THE CARRIER TO EACH CURRENT ENROLLEE AND PROSPECTIVE ENROLLEE AT THE TIME OF OPEN ENROLLMENT OR POLICY OR CONTRACT RENEWAL; AND
	(2) THE CONTRACT OR AN ATTACHMENT TO THE CONTRACT OF A PROVIDER BEING OFFERED A CONTRACT BY THE CARRIER TO RENDER HEALTH CARE SERVICES TO ENROLLEES OF THE CARRIER.
	(L) AFTER NOTIFYING A CARRIER AND PROVIDING AN OPPORTUNITY FOR A HEARING, THE COMMISSIONER MAY ISSUE AN ORDER UNDER § 4-113(D) OF THIS ARTICLE FOR A VIOLATION OF THIS SECTION.
19 20 21	(M) (1) THE COMMISSIONER MAY WAIVE THE APPLICATION OF THIS SECTION SUBSECTION (F) OF THIS SECTION FOR A CARRIER THAT HAS IN PLACE A PROCESS FOR EVALUATING EMERGING MEDICAL AND SURGICAL TREATMENTS USED FOR THE PURPOSE OF MAKING COVERAGE DECISIONS, IF THE COMMISSIONER DETERMINES THAT THE CARRIER'S PROCESS IS SUBSTANTIALLY EQUIVALENT TO, OR EXCEEDS, THE REQUIREMENTS OF THIS SECTION.
	(2) A CARRIER RECEIVING A WAIVER UNDER PARAGRAPH (1) OF THIS SUBSECTION SHALL REPORT ANY CHANGE IN ITS PROCESS FOR EVALUATING EMERGING MEDICAL AND SURGICAL TREATMENTS TO THE COMMISSIONER.
28 29	(3) THE COMMISSIONER MAY WITHDRAW A WAIVER GRANTED UNDER PARAGRAPH (1) OF THIS SUBSECTION WHENEVER THE COMMISSIONER DETERMINES THAT THE CARRIER'S PROCESS FOR EVALUATING EMERGING MEDICAL AND SURGICAL TREATMENTS IS NOT SUBSTANTIALLY EQUIVALENT TO THE REQUIREMENTS OF THIS SECTION.
31 32	(N) THE COMMISSIONER MAY ADOPT REGULATIONS TO CARRY OUT THIS SECTION.
33	
	5 399.8.
	AN INDIVIDUAL IDENTIFIED AND SERVING AS A CLINICAL EXPERT UNDER § 15-121 OF THE INSURANCE ARTICLE FOR THE PURPOSE OF EVALUATING EMERGING MEDICAL AND SURGICAL TREATMENTS IS IMMUNE FROM CIVIL LIABILITY FOR ANY

38 ACTION MADE IN GOOD FAITH IN CARRYING OUT THAT PURPOSE.

1 Article - Health - General

- 2 19-706.
- 3 (N) THE PROVISIONS OF § 15-121 OF THE INSURANCE ARTICLE SHALL APPLY
- 4 TO HEALTH MAINTENANCE ORGANIZATIONS.
- 5 SECTION 2. AND BE IT FURTHER ENACTED, That this Act shall take effect
- 6 October 1, 1997.